Patents by Inventor Mary S. Rosendahl

Mary S. Rosendahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10220075
    Abstract: Examples include a method of making a protein-PEG conjugate. The method may include providing an aqueous protein solution. The aqueous protein solution may include a protein, a pH buffer, and a chelating agent. The chelating agent may be chosen from the group consisting of an aminopolycarboxylic acid, a hydroxyaminocarboxylic acid, an N-substituted glycine, 2-(2-amino-2-oxocthyl) aminoethane sulfonic acid (BES), and deferoxamine (DEF). The method may also include introducing sodium cyanoborohydride and a methoxy polyethylene glycol aldehyde to the aqueous protein solution. The sodium cyanoborohydride in the methoxy polyethylene glycol aldehyde may have a molar ratio ranging from about 5:1 to about 1.5:1. The method may further include reacting the methoxy polyethylene glycol aldehyde with the protein to form the protein-PEG conjugate. The pH buffer may maintain a pH of the aqueous protein solution ranging from 4.0 to 4.4 during the reaction.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: March 5, 2019
    Assignee: REZOLUTE, INC.
    Inventors: Mary S. Rosendahl, Sankaram B. Mantripragada
  • Publication number: 20180334475
    Abstract: Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-? conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-?, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.
    Type: Application
    Filed: November 17, 2017
    Publication date: November 22, 2018
    Inventors: George N. Cox, Mary S. Rosendahl
  • Publication number: 20180318429
    Abstract: Examples may include a method of making a protein-PEG conjugate salt with increased hydrophobicity. The method may include providing an aqueous protein solution. This aqueous protein solution may include a protein and a pH buffer. The method may also include reacting a polyethylene glycol with the protein to form a protein-PEG conjugate. The method may further include protonating an amino group on the protein-PEG conjugate with a hydrophobic organic acid in an organic phase. The protonation may form the protein-PEG conjugate salt having a hydrophobic anion that increases the hydrophobicity-PEG conjugate salt.
    Type: Application
    Filed: July 11, 2018
    Publication date: November 8, 2018
    Applicant: Rezolute, Inc.
    Inventors: Mary S. Rosendahl, Sankaram B. Mantripragada, Eliana B. Gomez
  • Patent number: 10046058
    Abstract: Examples may include a microsphere. The microsphere may include a biodegradable polymer. Furthermore, the microsphere may include a protein mixture selected from the group consisting of a protein-polyethylene glycol conjugate, the protein-polyethylene glycol conjugate and the hydrophobic anion of the organic acid, a protein and the hydrophobic anion of the organic acid, and combinations thereof. Examples may also include a method of making the microspheres. The method may further include reacting a polyethylene glycol with a protein to form a protein-PEG conjugate. In addition, the method may include protonating an amino group on the protein-PEG conjugate with a hydrophobic organic acid to form the protein-PEG conjugate salt. Furthermore, the method may include mixing the protein-PEG conjugate salt in an organic solvent with a biodegradable polymer. The method may also include emulsifying the mixture.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: August 14, 2018
    Assignee: REZOLUTE, INC.
    Inventors: Mary S. Rosendahl, Sankaram B. Mantripragada, Eliana B. Gomez
  • Publication number: 20170362626
    Abstract: The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins.
    Type: Application
    Filed: January 24, 2017
    Publication date: December 21, 2017
    Inventors: George N. Cox, Daniel H. Doherty, Mary S. Rosendahl
  • Publication number: 20170015701
    Abstract: Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-? conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-?, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.
    Type: Application
    Filed: February 22, 2016
    Publication date: January 19, 2017
    Inventors: George N. Cox, Mary S. Rosendahl
  • Publication number: 20160354478
    Abstract: Examples include a method of making a protein-PEG conjugate. The method may include providing an aqueous protein solution. The aqueous protein solution may include a protein, a pH buffer, and a chelating agent. The chelating agent may be chosen from the group consisting of an aminopolycarboxylic acid, a hydroxyaminocarboxylic acid, an N-substituted glycine, 2-(2-amino-2-oxocthyl) aminoethane sulfonic acid (BES), and deferoxamine (DEF). The method may also include introducing sodium cyanoborohydride and a methoxy polyethylene glycol aldehyde to the aqueous protein solution. The sodium cyanoborohydride in the methoxy polyethylene glycol aldehyde may have a molar ratio ranging from about 5:1 to about 1.5:1. The method may further include reacting the methoxy polyethylene glycol aldehyde with the protein to form the protein-PEG conjugate. The pH buffer may maintain a pH of the aqueous protein solution ranging from 4.0 to 4.4 during the reaction.
    Type: Application
    Filed: May 19, 2016
    Publication date: December 8, 2016
    Applicant: AntriaBio, Inc.
    Inventors: Mary S. Rosendahl, Sankaram B. Mantripragada
  • Publication number: 20160244798
    Abstract: The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins.
    Type: Application
    Filed: January 15, 2015
    Publication date: August 25, 2016
    Inventors: George N. Cox, Daniel H. Doherty, Mary S. Rosendahl
  • Publication number: 20160151511
    Abstract: Examples may include a method of making a protein-PEG conjugate salt with increased hydrophobicity. The method may include providing an aqueous protein solution. This aqueous protein solution may include a protein and a pH buffer. The method may also include reacting a polyethylene glycol with the protein to form a protein-PEG conjugate. The method may further include protonating an amino group on the protein-PEG conjugate with a hydrophobic organic acid in an organic phase. The protonation may form the protein-PEG conjugate salt having a hydrophobic anion that increases the hydrophobicity-PEG conjugate salt.
    Type: Application
    Filed: November 30, 2015
    Publication date: June 2, 2016
    Inventors: Mary S. Rosendahl, Sankaram B. Mantripragada, Eliana B. Gomez
  • Publication number: 20160151510
    Abstract: Examples may include a method of making a protein-PEG conjugate salt with increased hydrophobicity. The method may include providing an aqueous protein solution. This aqueous protein solution may include a protein and a pH buffer. The method may also include reacting a polyethylene glycol with the protein to form a protein-PEG conjugate. The method may further include protonating an amino group on the protein-PEG conjugate with a hydrophobic organic acid in an organic phase. The protonation may form the protein-PEG conjugate salt having a hydrophobic anion that increases the hydrophobicity-PEG conjugate salt.
    Type: Application
    Filed: November 30, 2015
    Publication date: June 2, 2016
    Inventors: Mary S. Rosendahl, Sankaram B. Mantripragada, Eliana B. Gomez
  • Patent number: 9296804
    Abstract: Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-? conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-?, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: March 29, 2016
    Assignee: Bolder Biotechnology, Inc.
    Inventors: George N. Cox, Mary S. Rosendahl
  • Publication number: 20150374840
    Abstract: Provided are compounds and methods of making compounds containing two or three groups derived from a peptide, such as enfuvirtide or exenatide, covalently bound to a linker. The compounds may contain polyethylene glycol groups to enhance solubility and pharmacokinetic properties. The compounds are useful for the treatment of diseases or conditions subject to treatment with the parent peptide, such as HIV and AIDS in the case of enfuvirtide, or diabetes in the case of exenatide.
    Type: Application
    Filed: June 26, 2015
    Publication date: December 31, 2015
    Inventor: Mary S. Rosendahl
  • Publication number: 20150023918
    Abstract: Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-? conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-?, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.
    Type: Application
    Filed: November 25, 2013
    Publication date: January 22, 2015
    Applicant: Bolder Biotechnology, Inc.
    Inventors: George N. Cox, Mary S. Rosendahl
  • Patent number: 8932828
    Abstract: The present invention relates to novel methods for making and refolding insoluble or aggregated proteins having free cysteines in which a host cell expressing the protein is exposed to a cysteine blocking agent. The soluble, refolded proteins produced by the novel methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form PEGylated proteins.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: January 13, 2015
    Assignee: Bolder Biotechnology, Inc.
    Inventors: Mary S. Rosendahl, George N. Cox, Daniel H. Doherty
  • Publication number: 20140309168
    Abstract: Provided are compounds and methods of making compounds containing two or three groups derived from a peptide, such as enfuvirtide or exenatide, covalently bound to a linker. The compounds may contain polyethylene glycol groups to enhance solubility and pharmacokinetic properties. The compounds are useful for the treatment of diseases or conditions subject to treatment with the parent peptide, such as HIV and AIDS in the case of enfuvirtide, or diabetes in the case of exenatide.
    Type: Application
    Filed: March 19, 2014
    Publication date: October 16, 2014
    Applicant: AmideBio, LLC
    Inventor: Mary S. Rosendahl
  • Patent number: 8617531
    Abstract: Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-? conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-?, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: December 31, 2013
    Assignee: Bolder Biotechnology, Inc.
    Inventors: George N. Cox, Mary S. Rosendahl
  • Publication number: 20130217629
    Abstract: The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins.
    Type: Application
    Filed: September 14, 2012
    Publication date: August 22, 2013
    Applicant: BOLDER BIOTECHNOLOGY, INC.
    Inventors: George N. Cox, Daniel H. Doherty, Mary S. Rosendahl
  • Publication number: 20130137645
    Abstract: Provided are compounds and methods of making compounds containing two or three groups derived from a peptide, such as enfuvirtide or exenatide, covalently bound to a linker. The compounds may contain polyethylene glycol groups to enhance solubility and pharmacokinetic properties. The compounds are useful for the treatment of diseases or conditions subject to treatment with the parent peptide, such as HIV and AIDS in the case of enfuvirtide, or diabetes in the case of exenatide.
    Type: Application
    Filed: July 18, 2011
    Publication date: May 30, 2013
    Inventor: Mary S. Rosendahl
  • Publication number: 20130058895
    Abstract: Methods are provided using high pressure to treat aggregated interferons, to reduce the aggregate content of interferon material. In particular, recombinant human interferon-? may be so treated. Multiple strategies may be used in combination to make nonglycosylated IFN-? more amenable to high pressure treatment. When coupled with purification techniques, these strategies singly or in combination provide a low aggregate or substantially aggregate free, biologically active solution. In certain aspects, pharmaceutical compositions containing nonglycosylated interferon having less than about 5 weight percent of protein aggregation are provided.
    Type: Application
    Filed: July 27, 2012
    Publication date: March 7, 2013
    Applicant: NURON BIOTECH, INC.
    Inventors: Jeffrey L. Cleland, Stephen P. Eisenberg, Mary S. Rosendahl, Matthew B. Seefeldt
  • Patent number: 8329866
    Abstract: Disclosed are polymer sFlt-1 conjugates, variants of sFlt-1, compositions comprising such conjugates and variants, including cysteine variants of sFlt-1. Also disclosed is the use of such conjugates, variants and compositions in methods to inhibit the activity of VEGF, to inhibit angiogenesis, and to treat or reduce at least one symptom of diseases and conditions in which it is desirable to inhibit VEGF activity and/or angiogenesis.
    Type: Grant
    Filed: October 3, 2006
    Date of Patent: December 11, 2012
    Assignee: Bolder Biotechnology, Inc.
    Inventors: Mary S. Rosendahl, George N. Cox, III